Company news

Oryzon Genomics SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer’s Disease at the Virtual AAT-AD/PD 2020 Conference

April 3, 2020

ORYZON Reports Financial Results and Corporate Update for 4th Quarter and Year Ended December 31, 2019

February 24, 2020

ORYZON to Present at the 3rd Neuroscience Innovation Forum in San Francisco

January 8, 2020

ORYZON Presents New Efficacy Data From its Phase II Trial ALICE Investigating iadademstat in AML

December 9, 2019

ORYZON Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2019

October 28, 2019

ORYZON Presents New Positive REIMAGINE Efficacy Data of Vafidemstat in the Treatment of Aggression

October 3, 2019

ORYZON Presents Positive Efficacy Results on Iadademstat in ED-SCLC Patients at ESMO-2019

September 30, 2019

ORYZON Presents New Positive Efficacy Data on Vafidemstat for Treatment of Aggression

September 10, 2019

ORYZON’s Iadademstat Shows Efficacy Signs in Relapsed SCLC

September 9, 2019

ORYZON Reports Financial Results and Corporate Update for the First Half Ended June 30, 2019

July 30, 2019

ORYZON Announces End of Patient Recruitment for its Phase IIa Trials in Aggression with Vafidemstat: REIMAGINE and REIMAGINE-AD

July 29, 2019

ORYZON Raises Its Share Capital by EUR 20 Million Through a Private Placement

July 25, 2019

ORYZON Presents Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer's Association International Conference in Los Angeles

July 16, 2019

ORYZON to Present Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer's Association International Conference in Los Angeles

July 10, 2019

ORYZON Presents Preliminary Dose Finding Results of Phase II Trial With Iadademstat in AML

June 14, 2019

Oryzon Genomics to Present at the 18th Annual BIO CEO & Investor Conference 2016

February 2, 2016

Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease

February 1, 2016

Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors

December 30, 2015

ORYZON Files Clinical Trial Application in Spain for Phase I Study With ORY-2001 for Alzheimer’s Disease

December 16, 2015

Oryzon Genomics Announces Listing on Madrid Stock Exchange

December 10, 2015

ORYZON Announces the Appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as Independent Directors

November 4, 2015

Oryzon Announces Oral Presentation on ORY-2001 at 8th Annual Clinical Trials on Alzheimer's Disease Conference

November 2, 2015

ORYZON Raises $19 Million in Private Placement to Advance Therapeutic Programs

October 27, 2015

← Newer news releases

Decks

The 5 newest of 18 decks. Every deck is listed under its year.